Watch SMNRW. Know when insiders buy.
One email the day a filing lands. Free.
SMNRW
Semnur Pharmaceuticals, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$167.7MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.2M | −$4.3M | — | -0.02 | −$2.1M | — | — | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$4.6M | −$4.6M | — | -0.02 | −$2.7M | — | — | Aug 10 |
| Q4 2025 · Dec 31derived | — | — | — | −$6.2M | −$6.2M | — | -0.01 | −$3.6M | — | — | Feb 27 |
| Q3 2025 · Sep 30 | — | — | — | −$152.6M | −$152.6M | — | -0.76 | −$2.1M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$999K | −$999K | — | -0.01 | $268K | — | — | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$665K | −$665K | — | -0.01 | −$399K | — | — | Aug 10 |
| Q4 2024 · Dec 31 | — | — | — | −$776K | −$167K | −126.5% | 0.00 | −$1.4M | — | — | Feb 27 |
| Q3 2024 · Sep 30 | — | — | — | −$1.3M | −$1.3M | −305.8% | -0.01 | −$3M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$168K | −$1.1M | — | — | −$115K | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$368K | −$1.5M | — | — | −$374K | — | — | Nov 12 |
| Q4 2023 · Dec 31 | — | — | — | −$182K | $633K | — | — | −$159K | — | — | Apr 2 |
| Q3 2023 · Sep 30 | — | — | — | −$506K | $631K | — | — | −$76K | — | — | Nov 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$160.4M | −$160.4M | — | -0.78 | −$5.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$4.7M | −$4.7M | — | -0.02 | −$4.9M | — | — | $43.4M | — |
| FY2023 · to Dec 31 | — | — | −$3.2M | $633K | — | — | −$633K | — | — | $40.5M | — |
| FY2022 · to Dec 31 | — | — | — | −$419K | — | — | −$426K | — | — | — | — |
Every number comes from Semnur Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.